Upbeat Earnings Poise Stocks for More Gains
While investors have endured a great deal of adversity the last two years, there have been some signs that the…
Blog
A5 Laboratories Inc. (AFLB.OB) Completes Acquisition of Contract Research (CRO) and Interferon Production Technology
Yesterday, A5 Laboratories Inc. announced that they completed the acquisition of the Contract Research (CRO) and Interferon production technology previously…
VizStar, Inc. (VIZS.OB) Announces New Office Strategically Located in Los Angeles, California
VizStar, Inc., an upscale aviation charter transportation broker, announced this morning that the company has opened a new office in…
Fortress International Group, Inc. (FIGI.OB) Announces $44 Million in New Contracts for the First Half of 2010
Fortress International Group, Inc., a leading provider of consulting and engineering, construction management and 24/7/365 site services for mission-critical facilities…
Lexon Technologies (LEXO.OB) Inks Deal to Merge with INKTEK America Inc.
Lexon Technologies Inc., a manufacturer of recycles toner for laser printers, fax and multi-function copiers, today announced it has signed…
VLOV Inc. (VLOV.OB) Announces FY 2010 Guidance Lifted by Enhanced Designs and Brand Awareness
VLOV Inc., a China-based designer of VLOV brand men's apparel, today posted financial guidance for the fiscal 12 months ending…
XO Holdings (XOHO.OB) Subsidiary, XO Communications, Continues Expanding Footprint in Seattle Area
XO Communications announced today that they have expanded their network presence for the Seattle, WA market. Part of the XO…
Oilsands Quest Inc. (BQI) Updates Bitumen Resource Potential
Oilsands Quest Inc. released an updated assessment of its resource potential at several of its properties in Canada. McDaniel &…
American DG Energy Inc. (ADGE) Signs Private Placement Deal
American DG Energy Inc. announced that the company has signed a private placement agreement with an institutional investor. The company…
Industry Attention Turning to Cellceutix Corp. (CTIX.OB) as a Result of Cancer and Autism Research
Since Cellceutix began researching and developing Kevetrin for the treatment of multi-drug resistant cancers, the company's management team knew that…